Phase 1 Study Of KITE-753 in R/R B-Cell ALL

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT07674823
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • B-cell Acute Lymphoblastic Leukemia

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The goal of this clinical research study is to find the recommended dose of KITE-753 in patients with relapsed/refractory B-cell ALL. The safety of KITE-753 will also be studied.

Key Dates

Start date
Dec 31, 2026
Status verified
Jun 2026
Primary completion
Apr 1, 2029
Completion
Apr 1, 2031

Study Design

Enrollment
18 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment with KITE-753 CAR T-Cells
    Participants will be hospitalized during the treatment period from Day -1 prior to KITE-753 administration until a minimum of 7 days after KITE-753 administration (Day 7). Participants will remain in the hospital through day 7 post infusion of KITE-753 and not be discharged from the hospital until all CAR-T-related non-hematological toxicities return to grade ≤1 or return to baseline.

Primary Outcome Measure

Safety and Adverse Events (AEs) [ Time Frame: Through study completion; an average of 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UT MD AndersonHoustonTexas77030
Nitin Jain, MBBS
[email protected]
713-745-6080
Nitin Jain, MBBS (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By research site
UT MD Anderson· Houston, TX

Related Studies